TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Good Distribution Practices of Medicinal Products

Good Distribution Practices of Medicinal Products

Update to the HPRA’s Guidance Document on Good Distribution Practices of Medicinal Products for Human Use

 

Good Distribution Practices (GDP) ensure maintenance of product safety and quality during the transportation and distribution of medicinal products. The HPRA have recently updated their Guidance document to provide additional clarification to wholesalers and brokers located in Ireland regarding the GDP of Medicinal Products for Human Use (2013/C 68/01). Key updates to the document are as follows:

 

Outsourced Responsible Person (RP)

Outsourcing the role of the RP has become a common occurrence for wholesales in the industry today. The update to this guidance document states that Wholesalers who intend to outsource this role must have a contract in place to define, agree and control the activities that the RP will be responsible for. A system must also be in place in instances where the RP is not the signatory for GDP activates to demonstrate that the RP still maintains oversight of this approval.

Another important recommendation that the HPRA make in this is update is the need for a documented risk-based assessment to ensure that outsourced RPs have sufficient time allocated to complete their responsibilities.

Verification of Safety features

As of 9th Feb 2019, and in accordance with Commission Delegated Regulation (EU) 2016/161, wholesalers are required to verify the safety features on medicinal products received from suppliers that are not:

  • The manufacturer of the product
  • The MAH for the product
  • The wholesaler designated by the MAH

Wholesalers can verify the unique identifiers by scanning the 2D barcode on the product into the repository system, which is managed by Irish Medicines Verification Organisation (IMVO). The unique identifier is considered authentic when the repository contains an active unique identifier with a product code and a serial number that are identical to those being verified. The anti-tampering device is verified by physical examination. If the Wholesaler suspects that the product has been tampered with, they should deem the product not suitable for onward supply. Verification of safety features can be carried out at any stage between receipt and dispatch and the process should be documented in the company’s quality system.

Decommissioning of unique identifiers prior to supply

In general, wholesalers should decommission unique identifiers at the end of the supply chain i.e. where the medicinal product is supplied to the public. As per The Commission Delegated Regulation (EU) 2016 / 161 Article 23 wholesalers must decommission the unique identifier if the product is intended for to the supply to persons authorised or entitled to supply medicinal products to the public who are not a hospital or an in or out-patient/day patient clinic or health centre under the management or control of a hospital. The circumstances where a wholesaler must decommission unique identifiers are detailed in (a) – (k) of Article 23 of the Regulation and are as follows:

 

  • Persons authorised or entitled to supply medicinal products to the public who do no operate within a healthcare institution or within a pharmacy
  • Veterinarians and retailers if veterinary medicinal products
  • Dental practitioners
  • Optometrists and opticians
  • Paramedics and emergency medical practitioners
  • Armed forces, police or other government instructions maintaining stocks of medicinal products for the purpose of civil protection and disaster control
  • Universities and other higher education establishments using medicinal products for the purposes of research and education, with the exceptions of healthcare institutions
  • Prisons
  • Schools
  • Hospices
  • Nursing Homes

 

Promotional Samples / Sales Representatives

Samples of medicinal products that may be given to, or administered to, patients must be stored and transported to the end customer in accordance with GDP. Sales representatives may not hold or supply free medical samples unless there are systems in place to guarantee that those samples are not given to, or administered to, patients.

 

Establishment of the authority of customers to receive medicinal products;

The wholesaler is responsible to ensure the customers who receive medicinal products are authorised and entitled to do so. The wholesaler can do this by:

  • Obtaining a copy of the customers Wholesale Distribution Authorisation (WDA)
  • Checking the customers GDP certification
  • Performing periodic checks to verify the customers authority to receive medicinal product
  • Checking the EudraGMDP database eudragmdp.ema.europa.eu..

 

Storage

For areas, greater than a few square metres, where medicinal products intend to be stored a temperature mapping exercise must be performed. For areas less than a few metres, a risk assessment can be performed. Continuous temperature monitoring probes should be installed according to the Risk Assessment or mapping exercise to ensure that the appropriate conditions are maintained.

The guidance document can be viewed in full at the link below:

http://www.hpra.ie/docs/default-source/publications-forms/guidance-documents/ia-g0046-guide-to-good-distribution-practice-of-medicinal-products-for-human-use-v4.pdf?Status=Master&sfvrsn=23

PharmaLex has extensive experience in the provision of regulatory support regarding the transportation and distribution of medicinal products throughout EU and non-EU territories..

To discuss the range of GDP services that we offer, please connect with us on +353 1 846 4742 or email us at contactirl@pharmalex.com.

 

Related posts
Why collaboration and an Integrated Product Development program are key to successful drug development
Why collaboration and an Integrated Product Development program are key to successful drug development
14th June 2022
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • What was especially important to me was their ability to get a team, with the right experience, together so quickly.

    Mid-size Biotech
    Head of Outsourcing
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for